These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26283346)

  • 1. A broadly neutralizing human monoclonal antibody is effective against H7N9.
    Tharakaraman K; Subramanian V; Viswanathan K; Sloan S; Yen HL; Barnard DL; Leung YH; Szretter KJ; Koch TJ; Delaney JC; Babcock GJ; Wogan GN; Sasisekharan R; Shriver Z
    Proc Natl Acad Sci U S A; 2015 Sep; 112(35):10890-5. PubMed ID: 26283346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
    Baranovich T; Jones JC; Russier M; Vogel P; Szretter KJ; Sloan SE; Seiler P; Trevejo JM; Webby RJ; Govorkova EA
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2118-31. PubMed ID: 26787699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Wilson JR; Guo Z; Reber A; Kamal RP; Music N; Gansebom S; Bai Y; Levine M; Carney P; Tzeng WP; Stevens J; York IA
    Antiviral Res; 2016 Nov; 135():48-55. PubMed ID: 27713074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
    Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
    J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient.
    Li J; Yang Y; Wang M; Ren X; Yang Z; Liu L; Zhang G; Chen Q; Yang W; Chen YH; Wan X
    Antiviral Res; 2019 Oct; 170():104564. PubMed ID: 31336147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses.
    Wang J; Chen Z; Bao L; Zhang W; Xue Y; Pang X; Zhang X; Qin C; Jin Q
    J Virol; 2015 Sep; 89(17):9115-8. PubMed ID: 26063436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection Against H7 Subtype Influenza Virus Infection in Mice by Passive Transfer of Neutralizing Monoclonal Antibody.
    Zhang Z; Liu M; Zheng S
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):360-5. PubMed ID: 26492625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad neutralizing activity of a human monoclonal antibody against H7N9 strains from 2013 to 2017.
    Chen C; Liu Z; Liu L; Xiao Y; Wang J; Jin Q
    Emerg Microbes Infect; 2018 Nov; 7(1):179. PubMed ID: 30425238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.
    Thornburg NJ; Zhang H; Bangaru S; Sapparapu G; Kose N; Lampley RM; Bombardi RG; Yu Y; Graham S; Branchizio A; Yoder SM; Rock MT; Creech CB; Edwards KM; Lee D; Li S; Wilson IA; García-Sastre A; Albrecht RA; Crowe JE
    J Clin Invest; 2016 Apr; 126(4):1482-94. PubMed ID: 26950424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.
    Lee AC; Zhu H; Zhang AJ; Li C; Wang P; Li C; Chen H; Hung IF; To KK; Yuen KY
    Clin Vaccine Immunol; 2015 Dec; 22(12):1235-43. PubMed ID: 26446420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab')2.
    Zhao Z; Fan C; Duan Y; Zhang L; Li M; Yang X; Li R; Yang P; Wang X
    Int Immunopharmacol; 2014 Nov; 23(1):134-8. PubMed ID: 25192652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Antibody Response Contributes to the Virus Eradication and Clinical Recovery of H7N9 Influenza Infection.
    Liu X; Yang Z; Yuan J; Liao J; Duan L; Wang W; Zhang F; Chen X; Zhou B
    Ann Clin Lab Sci; 2017 Sep; 47(5):592-599. PubMed ID: 29066487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
    Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
    Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
    To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
    Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
    Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
    Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.